Durlobactam is a

beta-lactamase inhibitor Beta-lactamases (β-lactamases) are enzymes () produced by bacteria that provide multi-resistance to beta-lactam antibiotics such as penicillins, cephalosporins, cephamycins, monobactams and carbapenems (ertapenem), although carbapenems ...

used in combination with

sulbactam Sulbactam is a β-lactamase inhibitor. This drug is given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys the antibiotic An antibiotic is a type of antimicrobial substance ac ...

to treat susceptible strains of bacteria in the genus ''

Acinetobacter ''Acinetobacter'' is a genus of Gram-negative bacteria belonging to the wider class of Gammaproteobacteria. ''Acinetobacter'' species are oxidase-negative, exhibit twitching motility, and occur in pairs under magnification. They are important ...

'' It is an analog of

avibactam Avibactam is a non-β-lactam Β-Lactamase inhibitor, β-lactamase inhibitor developed by Actavis (now Teva Pharmaceuticals, Teva) jointly with AstraZeneca. A new drug application for avibactam in Ceftazidime/avibactam, combination with ceftazidim ...

. The combination therapy

sulbactam/durlobactam Sulbactam/durlobactam, sold under the brand name Xacduro (by Innoviva Specialty Therapeutics), is a co-packaged medication used for the treatment of bacterial pneumonia caused by '' Acinetobacter baumannii-calcoaceticus'' complex. It contains ...

was approved for medical use in the United States in May 2023.

See also

References

Further reading